muramylnac-ala-isogln-lys-tripeptide has been researched along with ifosfamide in 1 studies
| Studies (muramylnac-ala-isogln-lys-tripeptide) | Trials (muramylnac-ala-isogln-lys-tripeptide) | Recent Studies (post-2010) (muramylnac-ala-isogln-lys-tripeptide) | Studies (ifosfamide) | Trials (ifosfamide) | Recent Studies (post-2010) (ifosfamide) |
|---|---|---|---|---|---|
| 50 | 4 | 1 | 5,045 | 1,430 | 1,113 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernstein, ML; Betcher, D; Conrad, E; Ferguson, W; Gebhardt, M; Goorin, AM; Grier, H; Harris, MB; Healey, J; Huvos, A; Kleinerman, ES; Krailo, M; Link, M; Meyers, PA; Montebello, J; Nadel, H; Nieder, M; Sato, J; Schwartz, CL; Siegal, G; Weiner, M; Wells, R; Wold, L; Womer, R | 1 |
1 trial(s) available for muramylnac-ala-isogln-lys-tripeptide and ifosfamide
| Article | Year |
|---|---|
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Disease-Free Survival; Doxorubicin; Female; Humans; Ifosfamide; Infant; Male; Methotrexate; Osteosarcoma; Prospective Studies | 2005 |